Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | TLR2 | O60603 | 3/20 | 0.56 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.56 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362262 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL2267346 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL30885878 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL999302 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL12040103 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL1000135 | 0.99 | KMT2A (0.60) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL7392221 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL7815145 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL17669898 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL30441695 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250130235-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2025-04-24 | — | — | US | disclosed |
| EP-4466069-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024222960-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | 上海弼领生物技术有限公司 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024184332-A1 | TRACEABLE CHIMERIC ANTIGEN RECEPTOR CELL | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2024-09-12 | — | — | WO | disclosed |
| EP-4427759-A1 | TRACEABLE CHIMERIC ANTIGEN RECEPTOR CELL | Eberhard-Karls-Universität Tübingen (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-118632867-A | GLP-1/GIP receptor co-agonist prodrugs and uses thereof | 诺和诺德股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-112915210-B | Polyethylene glycol coupling drug, preparation method and application thereof | 重庆阿普格雷生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-113995847-B | Polyethylene glycol coupling medicine, preparation method and application thereof | 重庆阿普格雷生物科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230073036-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-03-09 | — | — | US | disclosed |
| CN-115697380-A | PTH analogs for treatment of hypoparathyroidism | 印第安纳大学研究与技术公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230019342-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-01-19 | — | — | US | disclosed |
| EP-3197912-B1 | LIPIDATED AMIDE-BASED INSULIN PRODRUGS | UNIV INDIANA RES & TECH CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4070820-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2022-10-12 | — | — | EP | disclosed |
| EP-4066861-A1 | POLYETHYLENE GLYCOL CONJUGATE MEDICAMENT, PREPARATION METHOD THERFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2022-10-05 | — | — | EP | disclosed |
| EP-4066860-A1 | POLYETHYLENE GLYCOL CONJUGATED DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2022-10-05 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-11371994-B2 | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11371994-B2 | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | PIK3CA, PIK3CB, AKT3 | KMT2A 1771/4885MDM2 2307/4885TLR2 3238/4885 |
| US-20230073036-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SLC10A1, FAR1, THEM6 | KMT2A 3642/4885MDM2 3177/4885TLR2 2760/4885 |
| US-20250130235-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, PIK3CB, AKT3 | KMT2A 1771/4885MDM2 2307/4885TLR2 3238/4885 |
| US-20230019342-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, PIK3CB, AKT3 | KMT2A 1771/4885MDM2 2307/4885TLR2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.